

**ANNUAL REPORT 2005**



Compiled on behalf of the Regional Malaria Control Commission



# Table of Contents

Overview.....	3
Section 1.....	7
Objective 1: To reduce malaria incidence in the border areas of South Africa and Swaziland from 250 per 1000 to less than 20 per 1000.....	7
Swaziland.....	7
South Africa.....	7
Objective 2: To reduce malaria infections from 625 per 1000 to less than 200 per 1000 within three year after the start of IRS in Maputo Province.....	9
Objective 3: To provide updated tourist information booklets containing definitive malaria risk maps and prophylaxis guideline.....	11
Objective 4: To develop a regional malaria control programme.....	12
Regional Management.....	12
Spray Programme in southern Mozambique.....	13
KAP in all countries.....	13
Gene flow.....	14
Malaria Vector Species and infection rates.....	15
Resistance in mosquitoes.....	16
Capacity development.....	16
Evaluation of direct impact.....	17
Objective 5: To develop a regional GIS based malaria information system.....	17
Section 2.....	20
SEACAT evaluation.....	20
Significantly reducing malaria transmission.....	20
Ensuring effective malaria treatment.....	21
Building human resource capacity.....	24
Monitoring and evaluation.....	24
Scientific manuscripts published to date.....	25
Scientific manuscripts submitted for publication include:.....	26
Scientific manuscripts in preparation.....	26
Thesis Completed.....	26
Comprehensive websites are maintained.....	26

## OVERVIEW

The Lubombo Spatial Development Initiative (LSDI) is a trilateral programme by the governments of Mozambique, Swaziland and South Africa to develop the Lubombo region into a globally competitive economic zone, ensuring sustainable employment and equity in access to economic opportunity in the region. The geographic region targeted by this initiative is an area linked by the Lubombo mountains and broadly defined as eastern Swaziland, southern Mozambique and north-eastern KwaZulu Natal.

Malaria was identified as a major deterrent to the development of the Lubombo region. This led to the creation of the Lubombo Malaria Control initiative, a cross-border collaboration aimed at the reduction of malaria throughout the LSDI area.

In July 1999 President Mbeki, President Chissano and His Majesty, King Mswati III signed the General Protocol which put in place a platform for regional cooperation and service delivery. In October 1999 the Lubombo Malaria Protocol and tri-national malaria programme was launched. The Malaria Protocol of understanding was signed at ministerial level between the three countries in October 1999. The malaria component of the LSDI project is managed by the Regional Malaria Control Commission (RMCC), a core group of experts, comprising of malaria control programme managers, public health specialists and scientists from the three countries.

The primary emphasis of the LSDI malaria control programme was to extend malaria control to southern Mozambique and thereby address a number of aspects central to increasing the effectiveness of malaria control in the two highest risk malaria provinces in South Africa and Swaziland, There was increasing consensus that even if malaria control measures were optimal in South Africa and Swaziland (with effective treatment and insecticides in place), the disease burden could only be further reduced by a regional approach to control. There is also increasing evidence that effective malaria control is a positive precursor to development with the situation prior to malaria control in South Africa supporting this view, given the well documented negative effects of malaria on tourism and agricultural development in the 1930's. The LSDI malaria programme was targeted at creating a platform for development, the beneficiaries being communities in areas with the lowest socio-economic development in the region as well as tourism, business and governments.

The effectiveness of the malaria control programme in the long-term will be assessed by the incidence of malaria over time in Mozambique as well as in the neighbouring malarious areas of South Africa and Swaziland. The success of intervention is not only measured using process (e.g. spraying and artemisinin-based combination therapy coverage) and biological markers (e.g.

parasite prevalence rates, health facility patient numbers and mosquito vector reductions), but also by the effects on tourism e.g. bed occupancy, job creation and risk perceptions, in all three countries over the course of the 7 year period (2000 – 2007).


The malaria vector control component in Mozambique has been implemented in phases (Figure 1) starting with Zone 1, in 2000, which is the area extending from the KwaZulu-Natal border to Maputo. Zone 1A is the area surrounding the MOZAL Plant which introduced malaria control as part of their social responsibility campaign, implemented in 2001. Phase three, initiated in 2002, focussed on Zone 2A comprising part of the Boane District, and Zone 2 and 3 extending north along the Kruger National Park border, covering an area of over 20 000<sup>2</sup> Km. The contiguous malaria control area in the region now exceeds 100 000<sup>2</sup> Km.

Since effective malaria control requires both vector control and early effective treatment, the RMCC decided to extend their objectives to ensure that the best malaria treatment was introduced across the LSDI. Widespread use of artemisinin-based combination therapy (ACT) offers the benefits of not only improving cure rates, but, unlike other malaria treatments, of also directly decreasing malaria transmission and potentially slowing drug resistance. To optimise the synergistic effects of IRS and ACTs on reducing malaria transmission and thus disease burden, while minimising programme costs, the implementation of ACTs has been timed to follow the establishment of effective vector control.

KwaZulu Natal was the first Ministry of Health in Africa to implement an ACT malaria treatment policy, when it introduced Coartem in January 2001. The planned phased implementation of ACTs, which resulted in their introduction in Mpumalanga in 2003 and in two districts in southern Mozambique in 2004, is ahead of schedule and will ensure that ACTs will be in place throughout the LSDI region by 2006. These changes are being comprehensively assessed through the South East African Combination Antimalarial Therapy (SEACAT) evaluation, which is nested within the LSDI.

From the baseline malaria season of 1999/2000 to 2004/2005, these improvements in malaria control have resulted in dramatic reductions in malaria incidence of over 98% in KwaZulu-Natal, over 70% in Mpumalanga and over 90% in Swaziland. Parasite prevalence in children has decreased by over 94% in Zone 1 Mozambique. The documentation of process and outcome indicators has supported evidence based decision making within the LSDI and has played a significant role in informing policy makers across the African region.

The original objectives of the LSDI Malaria Control Programme are clearly being met. This has largely been achieved through the rare strength of partnership between MRC, UCT, Private partners and Governments (both National and Provincial) who are equally committed to and share a common vision for ensuring malaria control in the region, primarily through indoor residual spraying and ACT implementation, with ongoing monitoring and evaluation to support evidence based decision making.



**Figure 1.** Malaria control Zones and baseline parasite prevalence rates at sentinel sites in Maputo Province, Mozambique.

This report is divided into two sections:

Section 1 reports on the overall objectives of the LSDI project, excluding drugs.

Section 2 reports specifically on the implementation of drugs and definitive diagnosis and associated research in the LSDI area.

## **Section 1.**

**Objective 1: To reduce malaria incidence in the border areas of South Africa and Swaziland from 250 per 1000 to less than 20 per 1000.**

### Swaziland

There was no evidence of any overall difference in risk of infection in children, compared to adults in any of the sites or years in which the parasite prevalence surveys were conducted (Odds Ratio 1.03, 95% CI 0.66 - 1.60,  $p=0.91$ ). Survey results for adults and children were therefore combined and prevalence rates were low at the 4 sentinel sites ranging from 2-8% in 1999. By 2003 these were all <3% and in 2005 averaged 0.25%. The malaria incidence rates over the same period reduced dramatically by >90% to 0.17%.

### South Africa

The border areas most influenced by the LSDI malaria programme are Komatipoort in Mpumalanga and Ingwavuma in KwaZulu-Natal. Prevalence surveys were in KwaZulu-Natal until the prevalence dropped below 10%. The prevalence at the three sentinel sites in KwaZulu-Natal ranged from 10 to 40% in 1999 with an average parasite prevalence of 19% in children and 17% in adults. By 2001 these parasite prevalence rates had dropped to below 5%. Malaria incidence rates reduced from the 1999/2000 baseline year to 2004/2005 by >98%.

Incidence data for the two localities are given in Figures 2 and 3. Although the scale of the disease differs in the different localities, the disease trends are similar. Significant reductions were made in these border regions once malaria control interventions had been implemented in adjacent areas in Mozambique. Indoor residual spraying was implemented in different years in the different zones in the LSDI area. Adjacent to Ingwavuma these measures were implemented in 2000/2001. In areas adjacent to Komatipoort, spray operations began in 2002/2003. In subsequent years, the number of cases decreased markedly and has remained low ever since.




Figure 2. Malaria incidence data for Komatipoort.




Figure 3. Malaria incidence data for Ingwavuma.

**Objective 2: To reduce malaria infections from 625 per 1000 to less than 200 per 1000 within five years after the start of IRS in Maputo Province**

A total of 15943 children between the ages 2 and <15 years were tested for parasitaemia at the sentinel sites in the 4 zones of the study area between December 1999 and June 2005 (Figure 4).

In zone 1, child and adult prevalence surveys were conducted at all sites in the first survey round in December 1999. The average infection rate in the younger age group was 64 % as opposed to 30 % in adults (relative risk 2.12; 95% CI 1.87 - 2.41, p<0.0001) with no evidence of heterogeneity in relative risks between sites (test for heterogeneity, p=0.90). Surveys in all subsequent years, and in other sites, were restricted to children between the ages of 2 and under 15 years.

In zone 1 prevalence surveys were conducted in December 1999 and June 2000 before spraying began. Since there was no evidence of any difference in prevalence between these two surveys in children at the 7 sites (p=0.82), site specific data from these two years were combined into a 2 year pre-spraying baseline and compared with prevalence values obtained from post spraying surveys undertaken annually in June for the period 2001 - 2004 after the first, third, fifth and seventh and 10<sup>th</sup> rounds of spraying. For zones 1A, 2 and 3, the prevalence surveys conducted in the years 2000, 2002 and 2003 respectively were used as pre-spraying baselines. The reductions obtained are reflected in Table 1.

Table 1. Results of the prevalence survey in Maputo Province showing annual reductions.

	1999	2000	2001	2002	2003	2004	2005	RELATIVE RISK *	EFFICACY **
<b>ZONE 1</b>	64.82	60.39	37.79	21.84	8.45	7.27	3.91	0.06	93.97
<b>ZONE 1A</b>		87.27	62.5	35.5	17.87	20.83	21.04	0.24	75.89
<b>ZONE 2A</b>	73.27	79.17	32.31	51.28	59.32	39.17	22.81	0.31	63.74
<b>ZONE 2</b>				69.42	34.07	29.87	20.32	0.29	70.73
<b>ZONE 3</b>					69.53	58.38	32.98	0.47	52.57

\*Relative Risk = prevalence 2005 / baseline prevalence

\*\*Efficacy = (baseline prevalence - prevalence 2005) / baseline prevalence

■ Baseline Prevalence      ■ 2005 Prevalence Results

*Plasmodium falciparum*  
Prevalence in Children Aged 2 to < 15  
BASELINE AND 2005 SENTINEL SITE SURVEYS: SOUTHERN MOZAMBIQUE

Baseline Survey:

Latest Survey (2005)




Figure 4. Sentinel sites for annual parasite prevalence surveys.

In Zone 2A baseline surveys in 1999 and 2000 showed 73 and 79% prevalence, respectively. Spraying was started in 2001 but due to financial constraints a permanent field officer was not assigned to the area and the spraying programme did not follow a fully structured plan as in the other areas until 2003 when funding became available (GFATM) (Figure 5). Parasite prevalence hereafter decreased as dramatically as in other areas.




Figure 5. Malaria prevalence pre and post spray (1999 – 2005).

**Objective 3: To provide updated tourist information booklets containing definitive malaria risk maps and prophylaxis guideline**

The tourism component of the project is progressing well. Surveys have now been completed in all SA provinces and are planned for expansion in Mozambique and Swaziland.

In the 1999/2000 malaria season, 18% of tourist facilities were in areas where 5 - 25 malaria cases per 1000 people were recorded, and 68% where in areas where the incidence was <5 per 1000 people. A major reduction in malaria cases was achieved by the 2002/2003 malaria season. None of the tourist facilities were in 5-25 malaria cases per 1000 people and 98% where in areas where < 5 malaria cases per 1000 people were recorded. The Greater St Lucia Wetland Park Authority has designated 10 development nodes within the park where local and international concerns will develop a wide range of tourist facilities from low-impact cabins to luxury hotels.

The tourism data is increasingly influencing tourism policy. SA tourism is using the "Malaria Free" campaign to enhance its international marketing strategy (Sunday Tribune, June 2004). General Manager , Corporate affairs, Tourism KwaZulu-Natal stated "This Study (MRC) is a model of how tourism can benefit the people and the economy".

#### **Objective 4: To develop a regional malaria control programme**

In order to develop a regional malaria control programme, a number of different activities had to be implemented.

##### Regional management

The Regional malaria Control Commission (RMCC) is the co-ordinating and decision-making body of the LSDI programme. The RMCC is tasked with facilitating the extension of control to the Mozambique sector, developing a regional MIS, implementing effective treatment and regional monitoring and evaluation, developing human capacity and managing funding. The RMCC is accountable to the participating Ministries of Health, the Regional Coordinating Mechanism, its funders and the Research Ethics Committees that have approved the LSDI monitoring and evaluation programmes. The RMCC meets quarterly and the venue for meetings is rotational between countries. Decisions impacting on the project are made by consensus and supported by evidence on specific issues and the broad experience of its members, with all members having equal input. The RMCC is responsible for reviewing the progress of the project in the respective countries and finding solutions to problems that may occur. The RMCC then presents its findings and recommendations to Governments, funders and the Regional Co-ordinating Mechanism (RCM). The RCM was set up as a GFATM requirement in 2003 to ensure good governance and appropriate expenditure of the Global Fund allocation.

The Medical Research Council, a South African institution set up to improve the nation's health status and quality of life through relevant health research, brought its well developed research support infrastructure to the table, including its Ethics committee, financial management systems, laboratories, staff and other management structures and international networks. This coupled to an experience base of co-ordinating large projects placed the MRC Malaria Research Programme in a position to undertake direct co-ordination of the day-to-day running of the programme on behalf of the RMCC, to provide secretarial, financial management, fund-raising and research support and to chair the RMCC. More recently the UCT has brought their services to the RMCC as well as the scientific monitoring and evaluation, and research training essential to malaria control.

### Spray programme in southern Mozambique

Malaria vector control through indoor residual spraying (IRS) of houses was introduced in Zone 1 in Mozambique with bendiocarb at 400mg per m<sup>2</sup> in November 2000. IRS was undertaken twice annually. The programme was incrementally extended with insecticide being applied twice annually starting in Zone 1A in February 2001, Zone 2 in October 2002 and in Zone 3 in February 2004 (Table 2) The four zones comprise an area of 20617 km<sup>2</sup> covering 7 districts.

Table 2. Stepped wedge design of Indoor residual spraying intervention in Maputo province, Mozambique, with Bendiocarb at 400 mg per m<sup>2</sup>

<b>Year</b>	2000	2001	2002	2003	2004	2005	Area (km <sup>2</sup> )
	<b>Cumulative Spray rounds</b>						
<b>Zone</b>							
1	* 2	4 <sup>§</sup>	6	8	10	11	7591
1A	*	2	4	6	8	9	407
2			*2	4	6	7	5723
3				*	2	4	6893

<sup>§</sup> spraying with Propoxur at 200mg per m<sup>2</sup>

# Baseline pre spraying cross sectional prevalence survey

House spraying with DDT started in Swaziland in 1981. Spray dates during the study period were September to December each year from 1999 to 2003. The application rate was 2g per m<sup>2</sup>.

House spraying with DDT in KwaZulu-Natal and Mpumalanga Provinces, South Africa started in the 1940's. In 1996 the policy changed to the exclusive use of a pyrethroid. After the emergence of pyrethroid insecticide resistance in the late 1990's, DDT spraying was reintroduced in KwaZulu Natal in February 2000, followed by a second round in June 2000 and in October for each of the subsequent years. The application rate was 2g per m<sup>2</sup>. DDT was reintroduced for house spraying in Mpumalanga Province, South Africa, in October 2001.

All spraying was conducted throughout using Hudson expert pumps with 4001 nozzles. Spraying personnel and managers were trained in spraying techniques, safety measures and personal protection equipment appropriate to the insecticide.

### KAP in all countries

A number of Knowledge, Attitude and Perception (KAP) were conducted in KwaZulu-Natal and Mpumalanga. KAP surveys were conducted in Mozambique in 1999, 2003 and 2005. However the results of these surveys were not utilised to identify gaps in the knowledge of the communities

under study. During April – May 2004 KAP surveys were carried out at community level in all the malarious Provinces of South Africa and Swaziland to identify lack of knowledge, with the intent of designing IEC strategies towards development of focussed malaria education programmes. These two parts of the strategy have been completed and IEC is being implemented in school and communities to reinforce awareness and knowledge of malaria and its treatment. A KAP survey will once again be conducted in 2006 to determine the impact of the IEC on malaria knowledge.

GIS (see objective 5)

### Gene flow

The emergence of drug resistance in the human malaria parasite, *Plasmodium falciparum*, is one of the major stumbling blocks in the control and eradication of malaria. Following the wide spread failure of chloroquine (CQ) as an antimalarial, sulfadoxine-pyrimethamine (SP) became the first line drug of choice in most countries plagued with disease. Despite being a combination drug, resistance to SP developed and spread rather rapidly which has impacted negatively on the race to roll back malaria. To ensure that newer antimalarials have a longer life span it is essential to understand the rate and extend at which drug resistance is spread as well as all the factors that underpin the onset of drug resistance.

Sulfadoxine-pyrimethamine disrupts the folate biosynthetic pathway by interacting with two enzymes, dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS) causing parasite death. Resistance to SP emerges as the result of point mutations in the genes coding for these enzymes, with a higher number mutations inferring a higher degree of resistance. To assess the level and extend of SP resistance we looked at four different point mutation sites in both the DHFR and DHPS genes which were thought to be associated with SP resistance using either sequence specific oligonucleotide probing and detecting polymerase chain reaction (PCR) dotblotting or nested PCR and restriction enzyme cleavage. Our preliminary results indicate that the peak in SP resistance in Southern Africa coincided with the emergence of two point mutations in the DHPS gene. The presence of three point mutations in the DHFR gene and two in the DHPS gene was also shown to be important predictors of SP failure.

Since point mutations are the main cause of drug resistance it was also essential to establish the evolutionary origin (gene flow or new mutations) of the drug resistance determinants as the origin would influence the measures taken to prevent/decrease the spread of resistance. Using microsatellite analyses we showed that SP resistance parasite from Tanzanian and Southern Africa share a common ancestor and thus it is likely that the spread of SP resistance in Africa is due to the spread of this lineage.

### Malaria Vector Species and infection rates

Malaria vector numbers as monitored by daily exit trap catches from 147 traps at 28 localities show dramatic reductions after spraying and in Zone 1 where spraying was started in 2000 there are >99% reductions both the *Anopheles funestus* group and *Anopheles gambiae* complex mosquitoes caught. Reductions in the other Zones i.e. 1A, 2 and 2A were in the range of 87-98% for *Anopheles funestus* group and 96-99% for the *Anopheles gambiae* complex.

#### *An. gambiae* complex

A total of 6178 *An. gambiae s.l.* were caught in the window traps prior to spraying and 737 post spraying, which constitutes a 93.5% reduction when corrected for trapping nights Three member species of the *An. gambiae* complex group (*An. arabiensis*, *An. merus* and *An. quadriannulatus*) were identified in all zones in Mozambique from both pre-spray and post-spray window trap collections. Prior to the commencement of spraying, *An. arabiensis* made up 84% of total *An. gambiae s.l.* mosquitoes identified with *An. merus* and *An. quadriannulatus* at 12% and 4% respectively. (Total number of *An. gambiae* complex identified prior to spraying =817).

Numbers of *An. gambiae s.l.* decreased rapidly after the first spray round and have continued to remain low. Of the sample of mosquitoes from the post spraying collections and subject to specific species identification, *An. arabiensis* numbers decreased proportionately (36% of the total) with the other members of the complex becoming proportionately more prevalent; *An. merus* 55% and *An. quadriannulatus* 9%. (Total number of *An. gambiae* complex identified post spraying =520).

#### *An. funestus* group

A total of 11217 *An. funestus* group. were caught in the window traps prior to spraying and 2069 post spraying, which constitutes a 90.5% reduction when corrected for trapping nights. Prior to spraying, four member species of the *An. funestus* group were identified, *An. funestus* (95%), *An. rivulorum* (<1%), *An. parensis* (<1%) and *An. lesoni* (4%). (Total number of *An. funestus* group identified prior to spraying =802)

Post-spraying results show a proportional decrease in the number of *An. funestus* (65%) and a relative increase in the other member species; *An. rivulorum* 28%, *An. vaneedeni* 3%, *An. parensis* 3% and *An. lesoni* 1%. *An. vaneedeni* was found in one location only, Zitundo, in the south-east of Zone 1. (Total number of *An. funestus* group identified post spraying=527).

Large variations in mosquito numbers and in species composition exist between zones and between sentinel sites within zones.

#### *Plasmodium* sporozoite rates

Molecular analysis to determine sporozoites rates was carried out on all positively identified mosquitoes. Sporozoite rates varied widely between zones and between pre and post-spraying. The pre-spraying rate for *An. gambiae s.l.* ranged from 0,84% to 10,9% (n=784) and post-spraying rates ranged from 0-1,22% (n=471)

*An. arabiensis* was found to be the major vector of the *An. gambiae* complex. *An. merus* was implicated as a minor vector in the eastern areas of Zone 1 where they were the predominant species.

The pre-spray sporozoite rate for *An. funestus s.s.* ranged between 4.69% and 5.28% (n=763). Post-spray rates ranged between 0 and 2.7%. (n=339) No other *A. funestus* member species was found to be infected.

#### Resistance in mosquitoes

Surveys were undertaken in December 1999, prior to implementation of IRS to ascertain which vector species occurred in Maputo Province and their susceptibility to the insecticides used in IRS. The initial proposal was to use pyrethroids for IRS in Mozambique, however the discovery of high levels of pyrethroid resistance by *Anopheles funestus* required the choosing of an alternative insecticide.

Insecticide resistance monitoring is an ongoing component of the monitoring and evaluation of the IRS programme.

#### Capacity development

The foundation of a successful, efficient and effective spraying programme is optimally trained staff at every level. Experience in this regard was lacking in Mozambique, and training was therefore a key priority before a spraying programme could be introduced. It was also conducted on an ongoing process once spraying started.

Training of field staff, whether spray operators or supervisors, followed a similar pattern i.e. 85% practical and 15% theory. However, supervisors received more in-depth training on environmental hazards, toxicity, first aid and safe handling/disposal of insecticides. Training of

supervisors and spray persons has taken place each year. The Mozambican programme managers assisted Mpumalanga in training their spray operators in 2002.

Training was extended to include intervention assessment and in this regard, window-trap caught mosquitoes were morphologically identified in Mozambique, and residual efficacy bio-assays carried out. The latter required the maintenance of an insectary and the ability to undertake both susceptibility and biochemical resistance testing which are increasingly being done in the country and will lead to a postgraduate degree. Training has been undertaken to equip field entomologists with the necessary research techniques, field staff to use global positioning system (GPS) receiver hand-held units, office staff in the use of the MIS and insectary staff in Maputo. Two students have completed MSc degrees through their work on the LSDI and one of them is registered at Liverpool School of Tropical Medicine for a PhD.

#### Evaluation of direct impact

Cross sectional parasite surveys were performed by the respective country malaria control programmes, at sentinel sites in the four Zones in Mozambique to which malaria control was extended and in South Africa and Swaziland at sentinel sites within 10 kilometres of the Mozambique border (Zone 1). HRP-2 antigen tests (ICT<sup>TM</sup> and Kat Medical) were used to assess prevalence of infection. Giemsa stained thick bloodsmear films were collected from a sub-sample of 1155 survey respondents from the Mozambican sentinel sites and examined microscopically by skilled microscopists for validation of the antigen test. At each of the 26 Mozambican sites at least one survey was conducted prior to the intervention to provide estimates of pre-spraying baseline prevalence of infection. A random sample of 120 individuals was taken for each survey at each sentinel site; sample size was powered to detect a significant change in prevalence based on an assumption of 20 % reduction in prevalence post intervention. Initial parasite prevalence surveys were conducted in the respective Zones in Mozambique in December 1999 (Zone1), June 2000 (Zone 1 and 1A), June 2002 (Zone 2) and June 2003 (Zone 3) with post intervention assessment in June of each subsequent year. Parasite prevalence surveys were carried out in KwaZulu-Natal in December 1999, June 2000, February and June 2001. Swaziland surveys were done in December 1999, and in June of each year thereafter. All age categories were sampled, with the exception of the surveys in Mozambique where this was only done in December 1999 and confined thereafter to children 2 to <15 years of age.

#### **Objective 5: To develop a regional GIS based malaria information system**

Malaria Information Systems (MIS) were developed and implemented for each of the partner-sectors with modifications being made on an ongoing basis. This computerised system allows the input, management and output of malaria case data which is used for both management and

research purposes. It includes a spatial component using a geographic information system (GIS) which is being customised to minimise end-user skill requirements and optimise access to the different data sets. The data collected during routine operations and entered into the MIS consists of both in- and out-patient data of confirmed and clinically diagnosed malaria cases. The input screens mirror the data collection forms and the automatic-linking and drop-down list minimising data entry errors.

Pre-designed outputs are provided in the form of maps, graphs or tables (i.e. number of can refills per week per person). This allows problems to be identified and addressed on an ongoing basis.

Spatial data has been collected for the region and includes administrative boundaries, population, health facility locations, towns and other relevant information. New sources are continually sought to ensure that current data at appropriate scales are provided.

The information systems provide for the management of two types of malaria-related data:

1. Malaria case data, and
2. Information relating to the malaria control activities, namely indoor residual spraying.

Malaria is a notifiable disease in all three countries requiring the recording of individual case details. Where testing capabilities do not exist, summary case records are kept of patients presumed to be infected with the malaria parasite.

In South Africa and Swaziland all cases are definitively diagnosed and definitive diagnosis has recently been implemented in Mozambique as part of the Global Fund initiative. Definitively diagnosed cases are essential to provide an overview within the country of the effect of malaria control activities as well as to monitor the regional effects of the LSDI malaria control programme. This is to be accomplished by ensuring that each MIS captures core data for comparative purposes while also allowing for the inclusion of local variables. Once definitive diagnosis has been implemented in Mozambique, incidence data (i.e. number of cases per annum) will be used to monitor control efforts when the malaria prevalence rates drop below 10%.

An important factor identified prior to the implementation of the spraying programme was the necessity to adequately supervise the spray operations. Due to the vast area to be sprayed, supervision of spray operators' activities on a daily basis was virtually impossible. A fourth generation relational database (MS Access) was therefore designed as an information repository for all spraying activities, and the data generated from computerized reports made it possible to evaluate productivity and spraying performance on an ongoing basis. Quality control was

undertaken by the malaria control programme managers of Swaziland, KwaZulu-Natal and Mpumalanga during each spraying round. Information regarding the indoor residual spraying activities is entered into the MIS to manage and monitor the efficacy of control in Swaziland, Mozambique, and the provinces of KwaZulu-Natal and Mpumalanga in South Africa. Data is entered onto spray-cards during routine spraying activities by the spray operators and then entered on a weekly basis into the MIS thereby allowing the insecticide application rates, number of structures sprayed and pump refills to be calculated per spray operator. This allows problems to be identified and addressed on an on-going basis.

Both components of the MIS (malaria case data and spray data) were designed in consultation with the Malaria Control Programme teams in the respective countries to ensure inclusion of the users requirements.

## Section 2

### SEACAT evaluation

#### 1. Significantly Reducing Malaria transmission

This objective is being achieved through community based indoor residual spraying with effective insecticides and through wide-spread use of artemisinin-based combination therapy as first line treatment.

The artemisinin derivatives, such as artesunate and artemether, have been selected specifically for their ability to reduce gametocyte carriage. Gametocytes are the stage of the Plasmodium falciparum life cycle responsible for transmission of malaria from the human host to the mosquito vector. Gametocyte carriage is being monitored in the *in vivo* studies of therapeutic efficacy.

In a randomised controlled trial in Namaacha and Catuane, southern Mozambique, gametocyte carriage at any follow up visit was significantly more prevalent following SP-monotherapy (30/65; 46%) than following the artesunate-SP combination (14/63; 22%);  $p=0.004$ . Area under the gametocyte time curve was significantly higher following SP-monotherapy than following the artesunate-SP combination ( $p=0.0074$ ). The prevalence and density of gametocytes in the LSDI area has been significantly reduced by the addition of artesunate to SP, even in areas which had high cure rates with SP monotherapy, such as Mpumalanga (Table 3). Similarly, in KwaZulu Natal, gametocyte carriage decreased significantly when SP monotherapy was replaced by artemether-lumefantrine treatment (Barnes et al., 2005).<sup>1</sup>

**Table 3: Gametocyte carriage in patients treated with SP monotherapy and artesunate plus SP in Mpumalanga.**

Gametocyte Carriage	Mpumalanga 2002 SP	Mpumalanga 2004 AS / SP
Cure rate	90%	99%
Post treatment prevalence	53.2% (75/141)	2.2% (2/92)
Gametocyte duration	3.5 days	0 days
Gametocyte AUC	490	0

---

**Barnes KI**, Durrheim DN, Little F, Jackson A, Mehta U, Allen E, Dlamini SS, Tsoka J, Bredenkamp B, Mthembu DJ, White NJ, Sharp BL. Effect of Artemether-Lumefantrine Policy and Improved Vector Control on Malaria Burden in KwaZulu-Natal, South Africa. PLOS Medicine 2005;2(11):e330

## **2. Ensuring effective malaria treatment**

There has been phased implementation of artemisinin-based combinations since 2001 when KwaZulu Natal was the first Ministry of Health in Africa to introduce artemether-lumefantrine as therapy as first line treatment policy. In January 2003, Mpumalanga introduced an artesunate plus SP treatment policy and in October 2004 Limpopo introduced an artemether-lumefantrine treatment policy. Each of these policy changes were entirely funded by the South African Department of Health.

In southern Mozambique, the phased district level implementation of artesunate plus SP has been supported financially by the Global Fund to fight AIDS, tuberculosis and malaria. This has been achieved in all 41 public sector health posts and health centres in Namaacha (March 2004), Matutuine (July 2004), Boane (January 2005), Marracuene (July 2005) and Magude districts (November 2005) (Figure 6). This well exceeds the LSDI target of 20 healthcare facilities. Achieving this ACT deployment at more healthcare facilities than initially planned within the defined budget has been made possible by the marked reduction in malaria case load following the effective community based indoor residual spraying and widespread use of ACTs, and by limiting treatment to only definitively diagnosed malaria cases. Rapid diagnostic tests are now being used for definitive diagnosis in all health centres and health posts in all LSDI districts except Matola, where they will be introduced in early 2006. The introduction of RDTs at community health post level (where chloroquine is the only antimalarial currently available and where treatment is dispensed by lay community members) is being piloted to determine whether RDT use results in better referral of confirmed malaria cases to the formal public sector and whether RDT use is adequately accounted for. This will be scaled up if the pilot is successful. ACTs will be introduced in Moamba and Matola districts later in 2006.

The efficacy of ACTs within the LSDI has been closely monitored through in vivo therapeutic efficacy studies with 6 week follow up. These have shown the ACTs to be highly effective across all study sites, and to be significantly more effective than monotherapy (Table 4).





Figure 6. Health facilities in Maputo Province that have ACTs and RDTs.

**Table 4: Therapeutic efficacy of SP monotherapy and ACTs within the LSDI**

	SP monotherapy	ACT	Level of significance
KwaZulu Natal (SP 2000 vs Coartem® 2002)	11%	99%	P<0.0001
Mpumalanga (SP 2002 vs SP plus Artesunate 2004)	90%	99%	p=0.013
Namaacha / Catuane RCT 2003	88%	96%	p=0.0612
Boane / Magude RCT 2004-5	91.5%	98%	p=0.0299

These drug and RDT systems have reduced stock-outs to a minimum – only 3/34 (10%) facilities recorded any stockouts between January and July 2005, compared with the target of <20%. All stockouts were of short duration.

The proportion of RDT clinically suspected malaria cases that are RDT positive varies by district and by age group (Figure 7). These results are consistent with the number of IRS rounds that



**Figure 7: Proportion of clinically suspected malaria cases that are rapid test positive, by district (January – June 2005).**

have occurred in each district.

### **3. Building human resource capacity**

Human resource capacity has been built in both the implementation of ACTs and RDTs and in monitoring and evaluation of these interventions. Effective ACT and RDT deployment required strengthening of the healthcare infrastructure including in service training of all healthcare providers at target healthcare facilities. Introductory training includes drug and RDT management, malaria diagnosis using RDTs (and smears), assessment of disease severity, treatment guidelines, indications for referral, record keeping and pharmacovigilance. This training is supported by regular on site supervisory visits and the provision of malaria treatment guidelines, drug management manual, pharmacovigilance handbook and adverse drug reaction reporting forms. To date, at least 255 healthcare workers have participated in this integrated training programme, well in excess of the target of 75.

Pharmaceutical services will be further strengthened by the creation of 20 intern posts in Maputo province for pharmacists who have just qualified, to serve as an apprenticeship during which they will be apprenticed to the LSDI health centres and receive training through specifically tailored curriculum to cover key components of the pharmaceutical service.

Academic training of core contributors to the LSDI is provided when the RMCC identifies a specific gap in knowledge or skill that is needed to meet the objectives of the LSDI. There are currently 15 professionals receiving such academic training at Diploma, Masters or PhD level, with 7 from Mozambique and 8 from South Africa. Field of further training include public health, tourism, drug and insecticide resistance, and drug safety.

### **4. Monitoring and evaluation**

Each component of the LSDI is comprehensively monitored, as reported above. This monitoring and evidence based policy is supported by the Geographic and Malaria Information Systems that are now fully functional in all LSDI study sites

## Scientific manuscripts published to date

1. Barnes, KI, Durrheim DN, Little F, Jackson A, Mehta U, Allen E, Dlamini SS, Tsoka J, Bredenkamp B, Mthembu DJ, White NJ, Sharp BL. Effect of Artemether-Lumefantrine Policy and Improved Vector Control on Malaria Burden in KwaZulu-Natal, South Africa. *PLOS Medicine* 2005;2(11):e330
2. Maharaj, R, Jotham, DJ & Sharp, BL. 2005. The impact of the reintroduction of DDT on malaria transmission in KwaZulu-Natal, South Africa. *South African Medical Journal*. 95 (11).
3. Roper C, Pearce R, Nair S, Sharp B, Nosten F and Anderson T. 2004. *Science* (20) 35: 1124.
4. Maharaj, R., Cassimiro, S., Mthembu, S.D. and Sharp, B.L. (2003) The residual life of bendiocarb: a field based evaluation from Mozambique. *Journal of Medical Entomology*. 40 (5)
5. Roper C, Pearce R, Bredenkamp B, Gumede J, Drakely C, Mosha F, Chandramohan D and Sharp B (2003) Antifolate antimalarial resistance in southeast Africa: a population-based analysis. *The Lancet*, 361, pp 1174-1181.
6. Booman M, Sharp BL, Martin CL, Manjate B, La Grange K and Durrheim DN. (2003) Enhancing malaria control using a computerized management system in southern Africa. *Malaria Journal* 2:13, 1-5.
7. Conteh L, Sharp BL, Streat E, Barreto A and Konar S. (2003) The Cost and Cost-Effectiveness of Malaria Vector Control by Residual Insecticide House-Spraying in Southern Mozambique: a Rural and Urban Analysis. *Tropical Medicine and International Health*, 9 (1), 125-132.
8. Muheki C, McIntyre D, Barnes K. Artemisinin-based combination therapy reduces expenditure on malaria treatment in KwaZulu Natal, South Africa. *Trop Med Int Hlth* 2004 (in press).
9. Stepniewska K, Taylor WRJ, Mayxay M, Smithuis F, Guthmann JP, Barnes K et al. The *in vivo* assessment of antimalarial drug efficacy in falciparum malaria; the duration of follow up. *Antimicrob Agents Chemother*. 2004; (in press)
10. Durrheim DN, Williams HA, Barnes KI, Speare R, Sharp BL, 2003. Beyond evidence: a retrospective study of factors influencing a malaria treatment policy change in two South African provinces. *Critical Public Health* 13 (4); 309-330.
11. Kachur SP, Abdulla S, Barnes K, Mshinda H, Durrheim DN, Kitua A, Bloland P. Mothers, malaria and resistance. *Trop Med Int Health* 2001; 6: 324-325.
12. Barnes KI, Folb PI 2004. Measuring Resistance to malaria treatment (Editorial). *S Afr Med J*; 94(1): 36-7.

13. Durrheim DN, Sharp BL, Barnes KI, 2001 Sentinel malaria surveillance - merely research or indispensable public health tool? Editorial . South African Medical Journal 2001; 91
14. Mabuza A, Govere J, Durrheim D, Mngomezulu N, Bredenkamp B, Barnes K, Sharp B 2001 Therapeutic efficacy of sulfadoxine - pyrimethamine for uncomplicated plasmodium falciparum malaria three years after introduction in Mpumalanga Province, South Africa. South African Medical Journal 2001; 91: 975-77 .
15. Bredenkamp BLF, Sharp BL, Durrheim DN, Barnes KI Failure of Sulfadoxine - pyrimethamine in treating Plasmodium falciparum malaria in KwaZulu Natal province. South African Medical Journal 2001; 91: 970 - 972
16. Baker L, Barnes K 2001 New antimalarial treatment in KwaZulu Natal South African Medical Journal 91 (5): 358-9.

**Scientific manuscripts submitted for publication include:**

1. Malaria morbidity and mortality following implementation of artemether-lumefantrine as first-line treatment of uncomplicated disease in KwaZulu-Natal, South Africa.
2. Therapeutic efficacy of sulfadoxine-pyrimethamine for treating uncomplicated Plasmodium falciparum malaria five years after implementation in Mpumalanga province, South Africa.

**Scientific manuscripts in preparation**

1. Malaria control in the Lubombo Spatial Initiative area of Mozambique, South Africa and Swaziland.
2. Malaria vectors, infectivity and control in southern Mozambique.
3. Knowledge, attitudes and perceptions in regard to malaria and health seeking behaviour in the LSDI area.

**Thesis Completed**

1. Casimiro, SLR (2003) Susceptibility and resistance to insecticides among malaria vector mosquitoes in Mozambique. MSc, University of Natal, Durban.
2. Maartens F (2003) Malaria risk in the Lubombo Spatial Development Initiative Area: A Perceptual and Scientific Analysis. MSc, University of Natal, Durban.

**Comprehensive websites are maintained**

[www.malaria.org.za](http://www.malaria.org.za)

[www.Lubombomapping.org.za](http://www.Lubombomapping.org.za)